Sonoma Pharmaceuticals, Inc. (SNOA) stock
SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3078% below fair value
$1.09−0.08 (-6.84%)
Close on Nov 13, 2026Market cap $5.22MP/E –Yield –
Sonoma Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Sonoma Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$1.27M. For fiscal 2026 it was -$2.32M. The highest annual figure on record is -$2.32M in fiscal 2026.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$2.32M | – |
| FY2025 | Mar 31, 2025 | -$3.57M | – |
| FY2024 | Mar 31, 2024 | -$4.53M | – |
| FY2023 | Mar 31, 2023 | -$4.45M | – |
| FY2022 | Mar 31, 2022 | -$5.70M | – |
| FY2021 | Mar 31, 2021 | -$3.22M | – |
| FY2020 | Mar 31, 2020 | -$7.08M | – |
| FY2019 | Mar 31, 2019 | -$10.81M | – |
| FY2018 | Mar 31, 2018 | -$13.70M | – |
| FY2017 | Mar 31, 2017 | -$12.73M | – |
| FY2016 | Mar 31, 2016 | -$14.47M | – |
| FY2015 | Mar 31, 2015 | -$6.41M | – |
| FY2014 | Mar 31, 2014 | -$5.77M | – |
| FY2013 | Mar 31, 2013 | -$3.11M | – |
| FY2012 | Mar 31, 2012 | -$6.14M | – |
| FY2011 | Mar 31, 2011 | -$7.11M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$8.00K | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$318.00K | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$644.00K | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$301.00K | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$1.06M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$625.00K | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$998.00K | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$815.00K | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$1.13M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$1.37M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$799.00K | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$1.16M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$1.20M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$1.11M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$1.80M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$703.00K | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$824.00K | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$3.01M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$921.00K | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$912.00K | -509.0% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$856.00K | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$2.77M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$58.00K | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $223.00K | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$612.00K | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$3.12M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$1.04M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$1.22M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$1.70M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$2.60M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$2.24M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$2.54M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$3.43M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$4.63M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$3.08M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$2.73M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$3.27M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$2.84M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$3.51M | – |
See a number that looks wrong?